Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Key Highlights
- ➤10 Afirma abstracts will be presented at ATA 2026, including two oral presentations.
- ➤Five studies independently conducted of Veracyte are included in the ATA program.
- ➤Afirma studies examine gene expression for thyroid nodule diagnosis and cancer aggressiveness.
- ➤GRID database research investigates preoperative diagnosis and thyroid cancer recurrence risk.
- ➤Johns Hopkins and MD Anderson presentations examine potential imaging and treatment targets.
Expert Statements
Phillip Febbo, Chief scientific and medical officer of Veracyte
“Patients facing a thyroid nodule diagnosis need to know whether they have cancer and, if they do, how that cancer might behave.”
Phillip Febbo, Chief scientific and medical officer of Veracyte
“These studies build on Afirma’s long-established role in thyroid nodule diagnosis and explore how gene expression data can help researchers answer additional questions about cancer risk and biology.”
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 10 abstracts involving its Afirma thyroid test will be presented at the 2026 Annual Meeting of the American Thyroid Association (ATA), November 4–7 in Philadelphia. The conference includes two oral presentations and eight posters, with five studies conducted independently of Veracyte.
The studies explore how gene expression can provide insights beyond individual genetic alterations to inform thyroid nodule diagnosis and assessment of cancer aggressiveness. Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets. Posters include studies using the Veracyte Genomic Resource for Intelligent Discovery (GRID) research database to investigate preoperative diagnosis and recurrence risk, as well as independent research on molecular testing and long-term outcomes.
Get started
Create a free account to read the full story.